Phase I/II open-label multicenter study of palbociclib in BRAFV600mut metastatic melanoma patients harbouring CDKN2A loss and RB1 expression and treated with vemurafenib (NCT 02202200)

导出原文传递

翻译打印收藏纠错

作者： Louveau, B. ^[1] ; Resche-Rigon, M. ^[2] ; Lesimple, T. ^[3] ; Da Meda, L. ^[4] ; Pracht, M. ^[5] ; Baroudjian, B. ^[6] ; Delyon, J. ^[7] ; Amini-Adle, M. ^[8] ; Dutriaux, C. ^[9] ; De Moura, C. Reger ^[10] ; Sadoux, A. ; Jouenne, F. ; Ghrieb, Z. ; Vilquin, P. ; Bouton, D. ; Tibi, A. ; Huguet, S. ; Rezai, K. ; Battistella, M. ; Mourah, S. ; Lebbe, C.

作者单位： Hop St Louis, APHP, CIC 1427, Paris, France ^[1] APHP, AGEPS, Paris, France ^[2] CHU, Lyon, France ^[3] Hop St Louis, APHP, Dept Pharmacol & Genom Tumeurs Solides, Paris, France ^[4] Hop St Louis, APHP, Dept Dermatol, Paris, France ^[5] APHP, DRCI, Paris, France ^[6] Univ Paris, INSERM, UMRS 976, Paris, France ^[7] Univ Bordeaux, INSERM, U1035, Bordeaux, France ^[8] Inst Curie, St Cloud, France ^[9] Ctr Eugene Marquis CHU CLCC, Unite Oncodermatol, Rennes, France ^[10]

发布时间 2021-09-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Fundamental & clinical pharmacology.

2021年35卷S1期

134-134页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase I/II open-label multicenter study of palbociclib in BRAFV600mut metastatic melanoma patients harbouring CDKN2A loss and RB1 expression and treated with vemurafenib (NCT 02202200)

Fundamental & clinical pharmacology.

相似文献

Fundamental & clinical pharmacology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I/II open-label multicenter study of palbociclib in BRAFV600mut metastatic melanoma patients harbouring CDKN2A loss and RB1 expression and treated with vemurafenib (NCT 02202200)

Fundamental & clinical pharmacology.

相似文献

Fundamental & clinical pharmacology.

相关期刊

检索历史清除